EZH2 and breast carcinoma: For example, the EZH2 PROTACs MS177 and MS8815 have been reported to be effective in inhibiting the growth of breast cancer cells [89] and PROTAC EZH2 degrader-1 in increasing sensitivity to cisplatin, etoposide, and teniposide in small cell lung cancer (SCLC) [90].